American Cancer Society. (2015, June 10). Breast Cancer. Retrieved from: http://www.cancer.org/cancer/breastcancer/index.
Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. (2014, July). Journal of Clinical Oncology. 32(21): 2255-2270.
Drugs and Health Products, Health Canada. (2017, November 7). Regulatory Decision Summary: Faslodex. Retrieved from: https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?linkID=RDS00452.
Eisen A, Fletcher GG, Gandhi S, Mates M, Freedman OC, Dent SF, Trudeau ME and members of the Early Breast Cancer Systemic Therapy Consensus Panel. Optimal systemic therapy for early breast cancer in women: a clinical practice guideline. (2015, March). Current Oncology. 22(S1): S67-S81.
Goss, PE, Ingle JN, Pritchard KJ, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. (2016, July 21). New England Journal of Medicine. 175(3): 209-219.
Joy AA, Ghosh M, Fernandes R, Clemons MJ. Systemic treatment approaches in HER2-negative advanced breast cancer - guidance on the guidelines. (2015, March). Current Oncology. 22(S!): S29-S42.
Morrow M, Burstein HJ, and Harris JR. Malignant tumors of the breast. DeVita VT Jr, Lawrence TS, & Rosenberg SA. (2015). Cancer: Principles and Practice of Oncology. (10th Edition). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 79: 1117-1156.
National Cancer Institute. (2015, July 8). Breast Cancer Treatment for Health Professionals (PDQ®).
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 2.2015). Retrieved from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.×